Tepezza use and a claim for hearing loss

Could I qualify for a Tepezza hearing loss claim?

A lawyer must review your use of Tepezza and the hearing harm you report. The label warns of hearing loss, but it does not prove the cause for one person. A review is a way to check the facts, not a promise that you qualify.

Start with your infusion dates, the name of your care team and the hearing changes you noticed. Include ringing in the ears if that was part of your experience. The transfer order describes claims of hearing loss and ringing, also called tinnitus. Keep your own account separate from a diagnosis you have not received.

If you had hearing loss before treatment, tell the lawyer and your care team. The 2024 hearing study included people with abnormal hearing at the start. That fact calls for a careful comparison of records; it does not set a legal rule that all such people qualify or are excluded.

For a family member, ask what permission is needed to obtain records and seek a review. The federal records guide covers access by patients and their personal representatives, with limits. Do not assume a family link alone lets you share all of another adult's health information.

How much money could a Tepezza claim bring?

This page cannot give you a supported payout range. A pending case count is not an award or an offer. Any money claim needs a review of the harm, proof and terms that apply to the case.

In a civil case, a person seeks relief for harm and must support the claim. Records of hearing care, bills and changes in daily life can give a lawyer facts to assess. A large number of cases does not establish what any one person will receive.

Do not treat a dollar amount on another page as your offer. Ask for the source, the case or group it concerns, and any terms that must be met. This source check did not verify current settlement terms; that limit is not a claim that no settlement exists.

What deadline could apply to my Tepezza claim?

There is no single filing deadline verified for every reader here. The law, the claim and your own dates matter. Ask a lawyer to check the time limit that applies to you.

Keep the dates of each infusion, first hearing change, hearing tests and discussions with your care team. Give the lawyer any prior case, release or lawyer agreement as well. These are facts to review, not a formula on this page for when a legal clock starts.

The FDA label date and the date of an MDL order are dates for those records. They do not establish your personal filing deadline. If someone gives you a deadline, ask for the law and the facts used to work it out. Do not assume time remains just because other cases are pending.

What happens when I check a Tepezza claim?

First, gather the dates and records you have. Next, ask a lawyer to check the possible claim, time limit and fee terms. A contact form is not the same as filing a court case.

A useful packet can include infusion records, hearing tests from before and after treatment, visit notes and bills. Mark gaps rather than filling them with guesses. Keep a copy of what you share so you can answer later questions from the same records.

Ask who is reviewing the packet and what happens next. If a lawyer takes the case, ask for the written agreement and the plan for a filing. A federal civil case starts with a complaint; sharing your story alone does not start one. Do not assume a web form means a firm has accepted you as a client.

What other questions do people ask about Tepezza hearing claims?

The questions below focus on hearing tests, follow-up and how to read the evidence. They do not supply a diagnosis or a firm's intake rules. A lawyer and your care team can address the parts that depend on your own records.

Ask about tests from before treatment, even if you do not have a copy yet. Ask what a six-month hearing result does and does not show. If eye symptoms improved while hearing changed, describe both rather than leaving one out. The benefit trial and hearing studies look at different outcomes.

A label warning, a count of court cases and a missing hearing test each mean different things. None alone resolves a person's claim. Ask for the source behind an answer and the part that still needs a review.

How Tepezza Causes Hearing Loss and Tinnitus

Tepezza (teprotumumab-trbw) is a monoclonal antibody approved in January 2020 for thyroid eye disease (TED). It works by blocking the insulin-like growth factor 1 receptor (IGF-1R), which plays a central role in the inflammatory orbital tissue expansion that characterizes TED. However, IGF-1R is also critically expressed in the inner ear — specifically in cochlear hair cells, the stria vascularis, and the spiral ganglion neurons that transmit auditory signals to the brain. By inhibiting IGF-1R throughout the body, Tepezza disrupts the maintenance and survival signaling these inner ear structures depend on, leading to sensorineural hearing loss, tinnitus, and autophony (hearing one's own voice or body sounds abnormally loudly). Clinical trial data showed hearing adverse events in approximately 10% of Tepezza patients compared to 0% in the placebo group — a signal that was inadequately disclosed in the original labeling. Post-market studies have since reported hearing changes in up to 65% of patients receiving the standard eight-infusion course.

IGF-1R Inhibition in Cochlear Hair Cells

The inner ear's outer hair cells — responsible for amplifying sound vibrations and enabling frequency discrimination — express high levels of IGF-1R. These cells rely on IGF-1 signaling for survival, metabolic support, and resistance to oxidative stress. When teprotumumab blocks IGF-1R systemically, cochlear hair cells lose this protective signaling. Unlike most cells in the body, cochlear hair cells in humans do not regenerate. Once damaged or lost, the hearing deficit is permanent. This mechanism explains why Tepezza-induced hearing loss is predominantly sensorineural (nerve-based) rather than conductive, and why it can persist long after the drug is discontinued.

Disruption of the Stria Vascularis and Endocochlear Potential

The stria vascularis is a highly vascularized tissue in the cochlea that generates the endocochlear potential — the electrochemical gradient essential for sound transduction. IGF-1R signaling is critical for maintaining the ion transport channels and cellular integrity of the stria vascularis. Tepezza's systemic IGF-1R blockade impairs strial function, reducing the endocochlear potential and diminishing the cochlea's ability to convert mechanical sound waves into electrical nerve impulses. This disruption manifests as a broad decline in hearing sensitivity across multiple frequencies and contributes to the tinnitus reported by many patients.

Spiral Ganglion Neuron Degeneration

Spiral ganglion neurons are the primary afferent neurons that carry auditory information from the cochlea to the brainstem. These neurons depend on neurotrophic support mediated in part through the IGF-1/IGF-1R signaling axis. Animal models have demonstrated that IGF-1 deficiency leads to progressive spiral ganglion neuron loss, reduced auditory nerve conduction, and elevated hearing thresholds. Tepezza's blockade of this pathway in humans is consistent with the pattern of progressive sensorineural hearing decline observed in treated patients, particularly those receiving the full eight-infusion protocol.

Eustachian Tube Dysfunction and Autophony

A distinctive feature of Tepezza-related otologic complaints is autophony — a condition in which patients hear their own voice, breathing, or heartbeat at abnormally high volume. This symptom is associated with eustachian tube dysfunction and patulous eustachian tube, both of which have been reported in Tepezza patients. The mechanism likely involves IGF-1R-mediated changes in the mucosal and cartilaginous tissues of the eustachian tube, leading to abnormal tube patency. While autophony is not hearing loss per se, it is a debilitating auditory disturbance that significantly impairs quality of life and is characteristic of Tepezza ototoxicity.

• No Regeneration of Human Cochlear Hair Cells: Unlike birds and some fish, mammals cannot regenerate cochlear hair cells. Once Tepezza damages or destroys these cells through IGF-1R blockade, the hearing loss is irreversible. This biological reality makes Tepezza ototoxicity fundamentally different from many other drug side effects that resolve when the drug is stopped.
• Cumulative Dose-Dependent Toxicity: Tepezza is administered as eight intravenous infusions over approximately 21 weeks. Clinical and post-market data indicate that otologic adverse events increase with cumulative dosing, with many patients experiencing hearing changes only after the fourth or fifth infusion — by which point significant cochlear damage may have already occurred.
• Patients who reported hearing changes mid-course were not consistently advised to discontinue treatment.
• Delayed Onset Masking Early Detection: Some patients do not experience noticeable hearing changes until weeks or months after completing Tepezza treatment, when irreversible cochlear damage has already been established. The delayed onset of symptoms complicates early detection and intervention.
• The American Academy of Otolaryngology has acknowledged Tepezza-associated hearing loss and recommends baseline and serial audiometric monitoring for all patients receiving the drug
• Post-market studies published in peer-reviewed otolaryngology journals report hearing changes in 65% or more of Tepezza patients — far exceeding the 10% rate reported in clinical trials
• The FDA required a label update in 2023 to strengthen warnings about hearing impairment, including the potential for permanent hearing loss, tinnitus, and autophony
• IGF-1R is well-established in the otologic literature as essential for inner ear development and maintenance, with animal knockout models demonstrating profound hearing loss in the absence of IGF-1 signaling
• Multiple ENT specialists have published case series documenting severe, bilateral sensorineural hearing loss in Tepezza patients that persisted more than one year after drug discontinuation

The Tepezza hearing loss litigation centers on the manufacturer's failure to adequately warn prescribing physicians and patients about the risk of permanent sensorineural hearing loss. The clinical trial data showed a clear 10% vs. 0% hearing adverse event signal, yet the original label characterized hearing events as generally reversible and did not recommend audiometric monitoring. Post-market evidence showing 65% hearing change rates has strengthened plaintiffs' claims that the risk was significantly understated. For affected patients — many of whom are women with thyroid eye disease who were promised a life-changing treatment — the permanent loss of hearing represents a devastating and undisclosed trade-off.

Regulatory History of Tepezza: From Accelerated Approval to Hearing Loss Warnings

Tepezza received FDA approval in January 2020 as the first and only drug approved for thyroid eye disease (TED). The approval was based on two clinical trials totaling 170 patients. While hearing adverse events were observed in the Tepezza arm and not in the placebo arm, the original prescribing information did not include a boxed warning, did not recommend audiometric monitoring, and characterized otologic events as generally reversible. As post-market reports of permanent hearing loss, tinnitus, and autophony accumulated through the FDA Adverse Event Reporting System (FAERS), the agency required label revisions strengthening the hearing warnings — but critics argue these changes came years too late for thousands of patients already treated.

The regulatory history of Tepezza reveals a pattern in which a clear clinical trial safety signal — 10% hearing adverse events vs. 0% placebo — was inadequately communicated in the original label, post-market evidence of much higher rates and permanent injury accumulated rapidly, and label corrections came years after thousands of patients had already been treated without appropriate audiometric monitoring or informed consent regarding the risk of permanent hearing loss.